The cost of certain procedures or treatments can be quite large and controlling these costs has bedeviled the health system for a long time. The public programs, Medicare and Medicaid, can deal with this issue to some extent by fiat–just saying we will only pay a set amount, which is limited only by political pressure that providers and suppliers may be able to exert. A new method being tried by commercial payers is to set a price that they will pay for the procedure or treatment and see which providers will accept that. A report from the Center for Studying Health System Change examines early experience with the method and identifies challenges in how it might be adopted by other payers. (CSHSC Report) The index case for reference pricing is CalPERS use of the technique in regard to hip and knee replacements. CalPERS invented enrollees to use hospitals for these procedures that would charge at or below a set price, and engaged in an extensive education effort to encourage use of these hospitals. Data showed prices from $15,000 to $110,000 for these procedures, with no distinguishable difference in quality. CalPERS decided to set the reference price at $30,000. Early results suggest that a number of procedures were moved to these facilities and many hospitals found it necessary to lower their prices to the reference price in order to keep business. There was no deterioration in quality and enrollees saved money. Some of the challenges for payers to utilize reference pricing is difficulty in getting enough cost and price information to set an appropriate reference price, fear of disrupting existing hospital relationships, and fear of upsetting enrollees who may have difficulty understanding the program. In addition, the total cost savings possible are limited because a relatively small number of procedures are likely to be amenable to reference pricing. And the technique only addresses unit cost, not the appropriateness of utilization. Nonetheless, every little bit of savings helps and anything that offsets the increasing market power of hospitals is very welcome.
By Kevin RocheDecember 13, 2013Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 21, 2023
Minnesota’s New Energy Insanity, Part 7
Minnesota is a particularly poor place to rely on solar power, but other states aren't…
March 21, 2023
A Quick SVB Follow-up
As I suspected, the SVB saga is primarily one of regulatory malfeasance, coupled with political…
March 19, 2023
Tom Frieden Speaks in the WSJ
A public health expert writes an article for the WSJ which amply demonstrates why Americans…